Toggle light / dark theme

Using Artificial Intelligence to Personalize Liver Cancer Treatment

For more information on liver cancer treatment or #YaleMedicine, visit: https://www.yalemedicine.org/stories/artificial-intelligence-liver-cancer.

With liver cancer on the rise (deaths rose 25% between 2006 and 2015, according to the CDC), doctors and researchers at the Yale Cancer Center are highly focused on finding new and better treatment options. A unique collaboration between Yale Medicine physicians and researchers and biomedical engineers from Yale’s School of Engineering uses artificial intelligence (AI) to pinpoint the specific treatment approach for each patient. First doctors need to understand as much as possible about a particular patient’s cancer. To this end, medical imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) are valuable tools for early detection, accurate diagnosis, and effective treatment of liver cancer. For every patient, physicians need to interpret and analyze these images, along with a multitude of other clinical data points, to make treatment decisions likeliest to lead to a positive outcome. “There’s a lot of data that needs to be considered in terms of making a recommendation on how to manage a patient,” says Jeffrey Pollak, MD, Robert I. White, Jr. Professor of Radiology and Biomedical Imaging. “It can become quite complex.” To help, researchers are developing AI tools to help doctors tackle that vast amount of data. In this video, Julius Chaprio, MD, PhD, explains how collaboration with biomedical engineers like Lawrence Staib, PhD, facilitated the development of specialized AI algorithms that can sift through patient information, recognize important patterns, and streamline the clinical decision-making process. The ultimate goal of this research is to bridge the gap between complex clinical data and patient care. “It’s an advanced tool, just like all the others in the physician’s toolkit,” says Dr. Staib. “But this one is based on algorithms instead of a stethoscope.”

Second malaria vaccine to win global approval is cheaper and easier to make

The World Health Organization (WHO) has endorsed a second malaria vaccine to protect children against the deadly disease, which killed 619,000 people in 2021.

Researchers say that the vaccine, known as R21, is easier to make than the first-approved malaria vaccine, called RTS, S, and will be cheaper per dose.

“There’s going to be enough of it to actually give out to children,” says Jackie Cook, a malaria researcher at the London School of Hygiene and Tropical Medicine.

Nano-mechanoelectrical approach increases DNA detection sensitivity by 100 times

UMass Amherst researchers have pushed forward the boundaries of biomedical engineering one hundredfold with a new method for DNA detection with unprecedented sensitivity.

“DNA detection is in the center of bioengineering,” says Jinglei Ping, lead author of the paper that appeared in Proceedings of the National Academy of Sciences.

Ping is an assistant professor of mechanical and , an adjunct assistant professor in and affiliated with the Center for Personalized Health Monitoring of the Institute for Applied Life Sciences. “Everyone wants to detect the DNA at a low concentration with a high sensitivity. And we just developed this method to improve the sensitivity by about 100 times with no cost.”

Mustafa Prize winner: Iran pioneer in nanotechnology, its medical advances amazing

An internationally-renowned Iranian scientist and this year’s winner of Iran’s prestigious Mustafa Prize for science and technology has hailed the country’s great advances in the fields of nanotechnology and medicine.

“Iran has always been far ahead in the field of nanotechnology,” Omid Farokhzad, who has won the prize for design, development, and clinical translation of novel polymeric nanomedicines used to treat various diseases, especially cancer, said on Monday.

New AI model can tell if you need lung cancer screening

Lung cancer screening is crucial for decreasing the death count from the disease but the government can’t scan everyone’s lungs. Here is an AI that identifies people who actually need screening.

Lung cancer is the deadliest cancer type, killing over a million people annually across the globe. The disease is responsible for the highest number of cancer deaths in both men and women in the US.

In fact, the death toll from lung cancer among women and men is nearly triple that of breast cancer and prostate cancer, respectively.

Dr. Alex Colville, Ph.D. — Co-Founder and General Partner — age1

Venture Investing To Catalyze The Next Generation Of Founder-Led, Longevity Biotech Companies — Dr. Alex Colville, Ph.D., Co-Founder and General Partner — age1.


Dr. Alex Colville, Ph.D. is Co-Founder and General Partner of age1 (https://age1.com/), a venture capital firm focused on catalyzing the next generation of founder-led, longevity biotech companies, with a strategy of building a community of visionaries advancing new therapeutics, tools, and technologies targeting aging and age-related diseases.

With a recent initial closing of US$35 million, age1 will be focusing on founders and companies at the earliest stages of first-money in, pre-seed and seed funding, and is resourced to continue to support companies through later rounds.

Dr. Colville previously established the biotech arm of Starbloom Capital and served as founding Chief of Staff of Amaranth Foundation, where he led: the foundation’s support of skilled researchers and ambitious moonshot projects in the longevity field, and helped to advance their lobbying efforts; the TIME Initiative (a group with mission to activate undergraduate students’ interest in aging biology); the Marine Biology Laboratory Biology of Aging Summer Course, among other programs.

Dr. Colville completed his Ph.D. in Genetics at Stanford University studying the biology of aging in Dr. Thomas Rando’s lab while consulting for several family offices, the R&D team of Rubedo Life Sciences, and the business development team of Maze Therapeutics. Prior to his Ph.D., while at Northeastern University completing his Bachelor of Science (B.S.) in Chemical Engineering with a Minor in Biochemical Engineering, he advised pharma companies as a management consultant at Putnam Associates, a boutique life sciences consulting firm.

Scientists Discover a Completely New Type of Enzyme That Helps Fight Genomic Parasites

Professor René Ketting’s team at the Institute of Molecular Biology (IMB) in Mainz, Germany, along with Dr. Sebastian Falk’s group at the Max Perutz Labs in Vienna, Austria, have discovered a new enzyme, PUCH, which plays a key role in preventing the spread of parasitic DNA

DNA, or deoxyribonucleic acid, is a molecule composed of two long strands of nucleotides that coil around each other to form a double helix. It is the hereditary material in humans and almost all other organisms that carries genetic instructions for development, functioning, growth, and reproduction. Nearly every cell in a person’s body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA).